Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

Research and Development for Sunesis. "Our combination study has shown complete remissions and a manageable safety profile. Both studies are continuing to enroll well, and, pending final clinical data, allow us to explore potential registration strategies in either newly diagnosed or first relapse AML populations."

Phase 2 Trial of Voreloxin in Platinum-Resistant Ovarian Cancer

Enrollment is complete for the Phase 2 study of voreloxin in platinum-resistant ovarian cancer. Three schedules of voreloxin have been studied, 48 mg/m2 given every three weeks (N=65), and 60 mg/m2 (N=37) and 75 mg/m2 (N=35) given every four weeks. As reported at the 12th Biennial Meeting International Gynecologic Cancer Society, two complete responses and five partial responses were observed at 48 mg/m2. Thirty patients (46%) achieved disease control, defined as stable disease for 90 days or more or a complete or partial response. Median progression free survival is 82 days. All patients at this dose level are now off-study. Data are maturing for both the 60 and 75 mg/m2 cohorts. One complete response and three partial responses of thirty-four patients for whom data are available are reported thus far at 60 mg/m2; nine patients remain on study. Early response data on ten patients at 75 mg/m2 show one partial response to date and five patients with stable disease; twenty patients remain on study. Voreloxin was generally well-tolerated at 48 and 60 mg/m2, with an incidence of febrile neutropenia of below 10%. An increase in febrile neutropenia is observed at 75 mg/m2, although the incidence remains below 20%.

About Voreloxin

Voreloxin is a novel naphthyridine analog, structurally related to quinolones, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-sele
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , September 2, 2015 BiondVax Pharmaceuticals ... the National Institute of Allergy and Infectious Diseases (NIAID), part ... Department of Health and Human Services (HHS), to launch a ... the United States in the 2015-16 timeframe. The ... candidate, Multimeric-001 (M-001), as a primer vaccine, which would be ...
(Date:9/2/2015)... ... September 02, 2015 , ... Whitehouse Laboratories is excited ... Pharma Ed Resources upcoming educational seminar and training session on Extractable & Leachable ... conference will provide Updates & Case Studies on the Latest Compliance Implications of ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... science research, today unveiled Genedata Screener ® version 13.0 at ELRIG Drug ... brings to market a rich set of new capabilities. Screener now supports High ...
(Date:9/1/2015)... , Sept. 1, 2015 The American ... Intent (LOI) for its Discovery Research Grant program. LOIs ... at 12:00 noon CDT. Discovery Grants ... with the potential to change current diagnostic or treatment ... grants specifically encourage novel research at its earliest stages, ...
Breaking Biology Technology:BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2
... Lentigen Corporation announced today,that it has received ... research (SBIR) grants to collaborate with leading,scientists. Through ... (LV) technology to the development of novel,immunotherapeutic treatments ... -- Melanoma, with Michael Nishimura, Ph.D, Associate ...
... 15 Baxa Corporation, a,Denver-based manufacturer of medical ... Marketing Association Gold Key Awards for its,integrated direct ... Colorado,s most highly acclaimed marketing competitions, the BMA,Gold ... on May 3rd at the,Cable Center at the ...
... a leading life sciences company, announced today that the ... Executive Officer,and a member of the Cambrex Corporation Board ... and Chief Executive Officer since 1995,and Chairman since 1999, ... the positions of Board Chairman and CEO and John ...
Cached Biology Technology:Lentigen Corporation Receives Four Research Grants From the National Institutes of Health 2Baxa Corporation Wins Two Colorado BMA 2008 Gold Key Awards 2Baxa Corporation Wins Two Colorado BMA 2008 Gold Key Awards 3Cambrex Appoints Steven M. Klosk as President and CEO 2
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
(Date:8/5/2015)... August 5, 2015 Transparency Market ... Recognition Market - Global Industry Analysis, Size, Share, Growth, ... for facial recognition is forecast to reach US$ 2,671.8 ... demand for surveillance systems by civil and government agencies. ... crimes and terrorist activities across the globe that would ...
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... retailer of wine products, BRSM Sales LLC, today announced the ... holiday shopping: www.GreatWineProducts.com . The new ... products including but not limited to: glass and stemware, burlap ... In addition to personal use, many items make ...
... the fight against pneumonia is the focus of ... University ePress., With an aim to establish an ... ,is a peer-reviewed, open-access journal which brings together ... Griffith,s Professor Allan Cripps is the Editor in ...
... 2013 New data suggest that the transcription ... Researchers determined that alcohol given to mice deficient ... alcoholic hepatitis. Further they found that although hepatitis ... in combination they suppressed FOXO3, reduced expression of ...
Cached Biology News:Griffith joins the fight against pneumonia 2Transcription factor may protect against hepatic injury caused by hepatitis C and alcohol 2Transcription factor may protect against hepatic injury caused by hepatitis C and alcohol 3
... uptake of long double stranded RNA (dsRNA) ... in a diverse group of organisms as ... interference leads to the inhibition of protein ... the target messenger RNA (mRNA). Attempts to ...
... Powerful exact mass measurements in ... orthogonal electrospray time-of-flight mass spectrometer (ESI-oa-TOF) ... machine in a format, which fits ... a mass resolution exceeding 10,000 FWHM ...
... Performance The TSQ Quantum Ultra defines ... bioanalytical and environmental analysis. It features ... APCI probes, a titanium skimmer with superior ... and sensitivity. Its redesigned ion transfer ...
... of long double stranded RNA (dsRNA) has ... a diverse group of organisms as well ... leads to the inhibition of protein expression ... target messenger RNA (mRNA). Attempts to induce ...
Biology Products: